|
pubmed:abstractText |
Immunomodulatory drugs have been shown to be only modestly effective in clinically definite relapsing remitting multiple sclerosis (RRMS). It has been hypothesized that their efficacy could be higher if used at the first appearance of symptoms, that is in the clinically isolated syndromes (CIS) suggestive of demyelinating events, a pathology which carries a high risk to convert to clinically definite MS (CDMS).
|
|
pubmed:affiliation |
Univeristà di Torino - Ospedale S. Luigi Gonzaga, Dip.to di Neuroscienze, Regione Gonzole, 10, Orbassano, Torino, Italy, 10043. marinellaclerico@libero.it
|
